Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment

被引：19
|
作者：
Han, Chanhee [1 ]
Bellone, Stefania [1 ]
Zammataro, Luca [1 ]
Schwartz, Peter E. [1 ]
Santin, Alessandro D. [1 ]
机构：
[1] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA
来源：
GYNECOLOGIC ONCOLOGY REPORTS | 2018年 / 25卷
关键词：
Binimetinib; MEK162; Low-grade ovarian cancer; Serous; Recurrent; Treatment-resistant;
D O I：
10.1016/j.gore.2018.05.011
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Background: Management of advanced/recurrent low-grade serous ovarian carcinoma (LGOSC) is often challenging. Effective treatment options remain limited for hormone and chemotherapy-resistant LGSOC. CASE: A 65-year-old woman with recurrent widespread LGSOC harboring the KRAS-G12 V hotspot mutation experienced a dramatic clinical response to Binimetinib (MEK162), a mitogen-activated protein kinase (MEK) inhibitor, after failing multiple chemotherapy and hormonal treatments. An 81% reduction of target lesions by RECIST 1.1 over 31 months of response duration was confirmed with serial CT scans. Episodes of drug-related toxicity (pneumonitis) easily resolved without sequelae with the use of oral steroids. Conclusion: Binimetinib may present a new treatment option for hormone-and chemotherapy-resistant LGSOC harboring KRAS mutations.
引用
收藏
页码：41 / 44
页数：4
相关论文
共 50 条
  • [1] Treatment of Recurrent Low-grade Serous Ovarian Cancer With MEK Inhibitors
    Kulkarni, Anjali
    Cooke, Carly
    Fazelzad, Rouhi
    Fung-Kee-Fung, Michael
    May, Taymaa
    Zigras, Tiffany
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (01): : 11 - 16
  • [2] The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician's choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.
    Monk, Bradley J.
    Grisham, Rachel N.
    Marth, Christian
    Banerjee, Susana N.
    Hilpert, Felix
    Coleman, Robert L.
    Pujade-Lauraine, Eric
    Pignata, Sandro
    Mirza, Mansoor Raza
    Oza, Amit M.
    del Campo, Josep M.
    Oehler, Martin Klaus
    James, Adam
    Christy-Bittel, Janna
    Barrett, Emma
    Boyd, Adam P.
    Vergote, Ignace
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician's choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
    Monk, Bradley J.
    Grisham, Rachel N.
    Marth, Christian
    Banerjee, Susana N.
    Hilpert, Felix
    Coleman, Robert L.
    Pujade-Lauraine, Eric
    Plgnata, Sandra
    Mirza, Mansoor Raza
    Oza, Amit M.
    del Campo, Josep M.
    Oehler, Martin Klaus
    James, Adam
    Christy-Bittel, Janna
    Barrett, Emma
    Boyd, Adam P.
    Vergote, Ignace
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Activity of the MEK inhibitor Binimetinib (MEK162) in combination with paclitaxel in patient-derived xenograft models of high-grade serous ovarian carcinoma
    Winski, Shannon L.
    Bouhana, Karyn
    Rhodes, Susan
    Cable, LouAnn
    Anderson, Deborah
    Williams, Lance
    Tunquest, Brian
    Logan, Tiffany
    Vigers, Guy
    Lee, Patrice
    CANCER RESEARCH, 2015, 75
  • [5] MEK inhibition for low-grade serous ovarian cancer: are we there yet?
    Scaranti, Mariana
    Mathias-Machado, Maria Cecilia
    Guo, Christina
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (01) : 155 - 156
  • [6] LATE BREAKING ABSTRACT: MEK162 (BINIMETINIB) IN CHILDREN WITH PROGRESSIVE OR RECURRENT LOW-GRADE GLIOMA: A MULTI-INSTITUTIONAL PHASE II AND TARGET VALIDATION STUDY
    Robison, Nathan
    Pauly, Jasmine
    Malvar, Jemily
    Gardner, Sharon
    Allen, Jeffrey
    Margol, Ashley
    MacDonald, Tobey
    Bendel, Anne
    Kilburn, Lindsay
    Cluster, Andrew
    Bowers, Daniel
    Dorris, Kathleen
    Ullrich, Nicole
    De Mola, Rebecca Loret
    Alva, Elizabeth
    Leary, Sarah
    Baxter, Patricia
    Khatib, Ziad
    Cohen, Kenneth
    Davidson, Tom Belle
    Plant, Ashley
    Bandopadhayay, Pratiti
    Stopka, Sylwia
    Agar, Nathalie
    Wright, Karen
    Nelson, Marvin
    Chi, Yueh-Yun
    Kieran, Mark
    NEURO-ONCOLOGY, 2022, 24 : 191 - 191
  • [7] Mutations in low-grade serous ovarian cancer and response to BRAF and MEK inhibitors
    Moujaber, Tania
    Etemadmoghadam, Dariush
    Mapagu, Cristina
    Kennedy, Catherine
    Chiew, Yoke-Eng
    Kan, Casina
    Nevins, Nikilyn
    Srirangan, Sivatharsny
    Fereday, Sian
    Traficante, Nadia
    Bowtell, David
    Balleine, Rosemary
    Harnett, Paul
    deFazio, Anna
    CANCER RESEARCH, 2018, 78 (13)
  • [8] MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype
    Gershenson, David M.
    Gourley, Charlie
    Paul, James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) : 3731 - +
  • [9] Targeting MAPK in recurrent, low-grade serous ovarian cancer Comment
    Blagden, Sarah P.
    LANCET, 2022, 399 (10324): : 499 - 501
  • [10] Stage I low-grade serous ovarian cancer: Is there a benefit to chemotherapy?
    Vue, Nujsaubnusi
    Horne, Zachary
    Crafton, Sarah
    Krivak, Thomas
    Miller, Eirwen
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S286 - S286
12345